These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9287400)
1. Comparison of Neoral and Sandimmun for induction and maintenance immunosuppression after kidney transplantation. Senel FM; Yildirim S; Karakayali H; Moray G; Haberal M Transpl Int; 1997; 10(5):357-61. PubMed ID: 9287400 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251 [TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Taesch S; Niese D Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220 [TBL] [Abstract][Full Text] [Related]
4. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
5. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P; Niese D Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620 [TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802 [TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Hoyer PF Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758 [TBL] [Abstract][Full Text] [Related]
8. Neoral use in the cardiac transplant recipient. Valantine H Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748 [TBL] [Abstract][Full Text] [Related]
9. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group. Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. Melter M; Rodeck B; Kardorff R; Hoyer PF; Brodehl J Transpl Int; 1997; 10(6):419-25. PubMed ID: 9428114 [TBL] [Abstract][Full Text] [Related]
11. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Qazi YA; Forrest A; Tornatore K; Venuto RC Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Coukell AJ; Plosker GL Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients. Kabasakul SC; Clarke M; Kane H; Karsten J; Clark G Pediatr Nephrol; 1997 Jun; 11(3):318-21. PubMed ID: 9203180 [TBL] [Abstract][Full Text] [Related]
14. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766 [TBL] [Abstract][Full Text] [Related]
15. The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts. Khajehdehi P; Yip D; Bastani B Clin Transplant; 1999 Apr; 13(2):176-80. PubMed ID: 10202614 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S; Markham A Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation. Amante AJ; Meier-Kriesche HU; Schoenberg L; Kahan BD Transpl Int; 1997; 10(3):217-22. PubMed ID: 9163863 [TBL] [Abstract][Full Text] [Related]
18. Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine. The Sandoz Neoral Study Group N103. Pescovitz MD; Wong RL; Choc MG; Chang CT Clin Transplant; 1997 Oct; 11(5 Pt 1):442-5. PubMed ID: 9361938 [TBL] [Abstract][Full Text] [Related]